Dr. Andrew Kin, M.D.
Claim this profileKarmanos Cancer Institute
Studies Lymphoma
Studies Amyloidosis
12 reported clinical trials
22 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
2Amyloidosis
Affiliated Hospitals
Clinical Trials Andrew Kin, M.D. is currently running
Iberdomide + Daratumumab
for Multiple Myeloma
The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The main questions it aims to answer are: * Assess if giving Iberdomide and the SC Daratumumab in the maintenance setting is an effective treatment and warrants further investigation in patients with residual disease * Is giving Iberdomide and SC Daratumumab maintenance post ASCT a safe option Participants will: * provide informed consent and complete screening assessments for eligibility within 28 days of starting treatment * Screening assessments include specific laboratory tests, a medical history assessment and a physical examination (including temperature, pulse, blood pressure, respirations, height and weight), an assessment of your heart function, a breathing test, cancer imaging, a bone marrow biopsy, minimal residual disease testing (MRD) and a questionnaire * If eligible, patients will start treatment with Iberdomide (1.0 mg on day 1-21 of each 28 day cycle, with an increase to 1.3 mg on Cycle 4 if the 1.0 mg dose was tolerated, to a maximum of 26 cycles or progressive disease, whichever is first) and SC Daratumumab (1800 mg SC on days 1, 8, 15 and 22 of cycle 1 and 2, then 1800 mg SC on Day 1 and 15 of cycle 3-6 and 1800 mg SC on Day 1 for cycles 7-26 to a maximum of 26 cycles or progressive disease, whichever is first) * while receiving treatment on study, physical exams (including temperature, pulse, blood pressure, respirations, height and weight), toxicity assessments, laboratory assessments and questionnaires will be done at various times over the course of the 26 cycles * an MRD assessment is required at 6, 12 and 24 months after starting treatment * End of treatment will occur once 26 cycles are completed, or cancer has progressed whichever comes first. At that time, specific laboratory tests, a physical examination (including temperature, pulse, blood pressure, respirations, height and weight), cancer imaging, a bone marrow biopsy and minimal residual disease testing (MRD) will occur.
Recruiting1 award Phase 210 criteria
Selinexor + Chemotherapy
for Non-Hodgkin's Lymphoma
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lymphoma.
Recruiting1 award Phase 1 & 214 criteria
More about Andrew Kin, M.D.
Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Andrew Kin, M.D. has experience with
- Daratumumab
- Tracking Dietary/Supplement Intake On MyFitnessPal Smartphone Application (app)
- NEXI-001 T Cell Product
- Moderna MRNA COVID-19 Vaccine
- Cyclophosphamide
- Polatuzumab Vedotin
Breakdown of trials Andrew Kin, M.D. has run
Lymphoma
Amyloidosis
Multiple Myeloma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Kin, M.D. specialize in?
Andrew Kin, M.D. focuses on Lymphoma and Amyloidosis. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Andrew Kin, M.D. currently recruiting for clinical trials?
Yes, Andrew Kin, M.D. is currently recruiting for 6 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Andrew Kin, M.D. has studied deeply?
Yes, Andrew Kin, M.D. has studied treatments such as Daratumumab, Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app), NEXI-001 T cell product.
What is the best way to schedule an appointment with Andrew Kin, M.D.?
Apply for one of the trials that Andrew Kin, M.D. is conducting.
What is the office address of Andrew Kin, M.D.?
The office of Andrew Kin, M.D. is located at: Karmanos Cancer Institute, Detroit, Michigan 48201 United States. This is the address for their practice at the Karmanos Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.